Q&A with Orr Inbar: CEO and Co-founder of Quant Health (online exclusive)
Q&A with Orr Inbar: CEO and Co-founder of Quant Health
By Andrew Humphreys | [email protected]
Med Ad News: 2023 was the year of AI-assisted blockbuster breakthroughs in FDA-approved therapies. How will AI play an even more impactful role in the biotech and pharma space throughout 2024?
Orr Inbar: 2024 will be the year that AI integration will be pivotal to the continued success of those working throughout biotech and life sciences, especially for those involved in the drug discovery and regulation processes. I anticipate we’ll begin to see a significant drop in clinical trial failure rates, a $45B a year issue, and this will have a duel impact of not only saving money for those looking to bring new therapies to market but also allowing these companies to take more shots on goal with the peace of mind of having a solid sense of how the clinical trials that they choose to move forward with will work out before they even get started.
Med Ad News: What are some of the AI trends to look out for this year within the pharmaceutical and health technology industries?
Inbar: One major trend will be the influx of repurposing therapies currently approved for one use to be fast-tracked for other uses. The most high-profile example of this in recent years that most folks would be familiar with is Semaglutide.
There is a massive opportunity for AI to supercharge the process of drug repurposing. For example, QuantHealth’s platform expedites this exact process. With QuantHealth, what used to take months or even years now takes weeks or hours. As this technology develops and further efficiencies are possible, I anticipate timeframes becoming even more condensed.
Med Ad News: How can AI develop transformative therapy solutions that go beyond optimizing resources, mitigating risk, and leveraging algorithms to supercharge the efficiency and effectiveness of drug trials?
Inbar: One of the most exciting components of AI is how it can be tuned to impact nearly every aspect of the drug development process. In that aspect, the sky’s the limit to where AI can make a real impact.
My background in data science, biomedical research, and AI led me to know that integrating AI into businesses is crucial to improving accuracy and efficiency across all industries, especially healthcare. At QuantHealth, we use AI to show our partners how to make smarter choices that create operational efficiencies, save money, and help reduce overall regulatory burden by allowing some parts of trials to be run virtually. We do this by visualizing potential outcomes and the tweaks that can be made depending on the endpoint goal and what the trade-off might be depending on the route they take. AI can provide a more holistic picture faster and more efficiently than ever.
Med Ad News: How is Quant Health using AI to expedite, de-risk, and optimize drug development?
Inbar: In one sentence, QuantHealth provides its partners with the blueprint for successful clinical trials.
Today, over 90% of experimental therapies that reach human trials fail to market. As a leader in biosimulation, in-silico trials, and synthetic evidence generation, we’re working with the pharmaceutical industry, academia, and regulators, hand in hand, to develop transformative AI solutions that dramatically increase the probability of success with an astounding 86% accuracy.
